The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial - Test2 - elhamkhani - TriplyDB

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

http://www.wikidata.org/entity/Q21195361

about

Allopurinol for chronic gout Febuxostat for treating chronic gout Febuxostat for treating chronic gout 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications Febuxostat Associations Between Hyperuricemia and Chronic Kidney Disease: A Review Uric acid and chronic kidney disease: which is chasing which?Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal Gouty Arthritis: A Review of Acute Management and Prevention.Treatment approaches and adherence to urate-lowering therapy for patients with gout.Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study Uric acid as one of the important factors in multifactorial disorders--facts and controversies.Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome African American patients with gout: efficacy and safety of febuxostat vs allopurinol.Efficacy and safety of febuxostat in elderly female patients.The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.2011 recommendations for the diagnosis and management of gout and hyperuricemia.Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease [The etiology and management of gout].The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.An update on the pathology and clinical management of gouty arthritis.Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.Efficacy and safety of febuxostat in patients with hyperuricemia and gout.Uric acid as a target of therapy in CKD.Prophylaxis on gout flares after the initiation of urate-lowering therapy: a retrospective research.Latest evidence on gout management: what the clinician needs to know Chronic hyperuricemia, uric acid deposit and cardiovascular risk The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.Predicting allopurinol response in patients with gout 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones

P2860

Q24193107-B9221B31-2454-4A78-A932-7EA2BBDD6FDB Q24202984-E089D8B2-0A75-4C22-A3B0-85516CB5DED5 Q24236637-13F14FD2-F4A3-46DB-8B78-824E9160D27A Q24612292-7D39817C-D9A8-43E6-AF70-3C230D8A5C3E Q24658504-34D123BD-6D31-404A-8085-F5AFCEAB1445 Q26738948-AEF7288A-986A-4770-B096-9784F81E559C Q26773263-AACC5136-B5B2-4B57-82E7-2EF6A8DB8F1C Q26796333-2DE7DD27-3B75-4B06-B870-E3115C05870C Q26824554-6F1EB181-31C1-40F9-917D-F869F4075F44 Q26862468-5A5C2722-24C4-46C0-AF8C-2153FEAF378D Q30249531-CEF07187-0857-4735-A659-58AECE7C8CEF Q33597442-BCDE6A04-B82C-4DA4-ACC8-F5BCD6BA46FB Q33706623-E5A6EA26-152E-4127-85CC-E7F8038F604F Q33773142-268040C7-A402-48E9-A760-ACDCA8C81BFF Q34141630-38510806-69D1-45F9-A80E-74EE10C21D7B Q34153554-C43985FD-628B-497A-B1F6-B409DDE74B7C Q34154666-D40029E9-6BBF-4507-B9D2-DB8237CC2827 Q34204854-645125B7-706B-40EC-AA65-8B405CD8AEB1 Q34250995-2DD253D8-9467-404C-8C0E-08F6E83FF51B Q34317722-98E2A2C6-B544-4EF5-88C9-78AB60F4884C Q34636225-2F9C4914-4AC7-4EB3-A7DC-28205F2C88FF Q34877729-6228C423-0365-4AB4-9A72-B8B8A9BD6F77 Q35012174-0EF10FF6-1CBF-4255-899F-84160E1B2625 Q35528880-5BA48636-A665-4C5C-B70A-EFD79F4416BC Q35643985-32B07809-6B4E-4BD0-B092-C9074E960E73 Q35775875-613BE748-7CB7-424E-AA5B-4751F463AB37 Q36059557-B5038E89-D0F2-4ED7-A71C-9E5745BC01CD Q36476464-D39D5582-5A53-46C8-88D5-299882717E11 Q36493145-CAAEE43D-C192-4C7F-A6D5-91787AF09A44 Q36515484-8E2182D0-1209-4D41-9524-A48757C53830 Q36712438-085CDAB4-C095-4D7A-93E6-D6B4461B4D15 Q36779141-8E49459F-8A7B-4E20-8FB3-FEA8848A7563 Q36802064-69AEB79F-E42D-4EA7-AA3C-D329E890A1C5 Q36870924-E538B07A-15F4-402B-BB07-97E0B583DD8A Q36903272-67C36262-6B41-4224-B069-83CA45157142 Q36981450-562373E4-EE17-48D4-85DE-20BE6A7D1923 Q37041741-B2B45C83-DB23-4E0F-B164-3CD01E41F0F8 Q37208467-22FE7373-FA56-4031-97E9-A577A96CD66F Q37240086-0D0D77DF-B6C5-4339-8F13-B68138C4E7DA Q37280815-77EEE2EE-729A-47B6-92D5-5DCFC87A2EDB

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

http://www.wikidata.org/entity/Q21195361

description

2010 nî lūn-bûn

@nan

2010 թուականին հրատարակուած գիտական յօդուած

@hyw

2010 թվականին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@ast

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@en

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@en-gb

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@nl

type

label

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@ast

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@en

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@en-gb

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@nl

prefLabel

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@ast

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@en

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@en-gb

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@nl

P1433

Q21195361-D06AB933-A31D-47B6-B9F7-D60C1CF2F7C1

P1476

Q21195361-8714AA6E-4D38-4D5F-9423-05005EEAC421

P2093

Q21195361-10339844-5960-40BF-BB4A-B0EA5908D410

Q21195361-16F0CE53-58C9-4560-9BE3-56B344E854E2

Q21195361-2CEAD2DC-85CC-4101-B3CE-2A4B10FEAFE4

Q21195361-8EC80F0B-5A5C-4266-9324-762E9803328C

Q21195361-C2693A08-96CE-4B40-8255-8B4CDF89550B

Q21195361-D918E009-F1AA-4029-BFE5-CF9DEA6A7F6B

Q21195361-DD715CEE-FCA9-4399-A171-4A48F7A70E69

P2860

Q21195361-02C9BF57-8C63-4F08-9EBE-14039A4C0E81

Q21195361-06EA4143-CD67-449C-A7DD-44C9A4604D6A

Q21195361-07D339E6-3739-4175-86C8-6B6CF723E87B

Q21195361-0876A02F-86A7-44E6-8388-B4F1A7AF9A98

Q21195361-0CEA6474-BFA9-4479-ABEF-BAFF7B9FE43A

Q21195361-16EA66B1-0152-4FA6-A917-8311A3D8455F

Q21195361-170E5C72-E6CA-4572-A8D9-3EC2AFA08278

Q21195361-1AC4CC87-3077-4BE8-A137-FEA7CA597B16

Q21195361-1E1CA65B-6D96-436B-AB8A-0A4C4E4A2582

Q21195361-26FC552D-75A7-4AA4-8252-C8C26C4330F0

P2888

Q21195361-E75EE1E6-3FA7-4301-8763-BA76A1D7AA1E

P304

Q21195361-6FD5B479-C2A7-4C94-8E90-D91D6090F948

P31

Q21195361-7AEDA1E9-C503-49E0-934D-70F696E22EBC

P3181

Q21195361-6C4C7635-76AF-497D-A9A8-E2A9FE6A9EC0

P356

Q21195361-3752887A-1D0D-4E85-A366-54AB9309D855

P407

Q21195361-76571DCD-4109-4316-8F86-0D5DDA310AA9

P433

Q21195361-17470A3D-514B-4C02-9852-A7D9D30915F5

P478

Q21195361-156D9050-C056-4A53-A380-56306BE2CB07

P577

Q21195361-530ACEB9-A6F6-45A4-A95F-8EA8E63D3E70

P5875

Q21195361-E68927D1-6643-456E-B413-B26F3D6AC132

P6179

Q21195361-F724F933-FA4A-40D9-B135-7B3E65707424

P698

Q21195361-C45BFB69-BD5F-451D-A354-CFF88833F692

P932

Q21195361-7CEFFE97-B2B2-4836-8D3B-426B88739943

P3181

P356

P1433

Arthritis Research and Therapy

P1476

The urate-lowering efficacy an ...... ia of gout: the CONFIRMS trial

@en

P2093

Alvin F Wells

http://www.w3.org/2001/XMLSchema#string

Christopher Lademacher

http://www.w3.org/2001/XMLSchema#string

Eric Lloyd

http://www.w3.org/2001/XMLSchema#string

H Ralph Schumacher

http://www.w3.org/2001/XMLSchema#string

Luis R Espinoza

http://www.w3.org/2001/XMLSchema#string

Michael A Becker

http://www.w3.org/2001/XMLSchema#string

Patricia MacDonald

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

Prediction of creatinine clearance from serum creatinine

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

Synovial fluid analysis for diagnosis of intercritical gout.

Serum urate levels and gout flares: analysis from managed care data.

Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

P2888

P304

R63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

582770

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/AR2978

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43049217

http://www.w3.org/2001/XMLSchema#string

P6179

1042889871

http://www.w3.org/2001/XMLSchema#string

P698

20370912

http://www.w3.org/2001/XMLSchema#string

P932

2888216

http://www.w3.org/2001/XMLSchema#string